BIOMAT Database Logo BIOMAT Database Logo

Ethical issues in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. 1997

S G Post, and B Beerman, and H Brodaty, and A W Gaines, and S G Gauthier, and D S Geldmacher, and S Hill, and A Homma, and M N Rossor, and P J Whitehouse, and B Winblad
Center for Biomedical Ethics, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.

UI MeSH Term Description Entries
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003431 Cross-Cultural Comparison Comparison of various psychological, sociological, or cultural factors in order to assess the similarities or diversities occurring in two or more different cultures or societies. Transcultural Studies,Comparison, Cross-Cultural,Comparisons, Cross-Cultural,Cross Cultural Comparison,Cross-Cultural Comparisons,Studies, Transcultural,Study, Transcultural,Transcultural Study
D003704 Dementia An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness. Senile Paranoid Dementia,Amentia,Familial Dementia,Amentias,Dementia, Familial,Dementias,Dementias, Familial,Dementias, Senile Paranoid,Familial Dementias,Paranoid Dementia, Senile,Paranoid Dementias, Senile,Senile Paranoid Dementias
D004339 Drug Compounding The preparation, mixing, and assembly of a drug. (From Remington, The Science and Practice of Pharmacy, 19th ed, p1814). Drug Formulation,Drug Preparation,Drug Microencapsulation,Pharmaceutical Formulation,Compounding, Drug,Formulation, Drug,Formulation, Pharmaceutical,Microencapsulation, Drug,Preparation, Drug
D004994 Ethics, Pharmacy The principles of proper professional conduct concerning the rights and duties of the pharmacist, relations with patients and fellow practitioners, as well as actions of the pharmacist in health care and interpersonal relations with patient families. (From Stedman, 25th ed) Ethics, Pharmaceutic,Ethics, Pharmaceutical,Pharmaceutic Ethics,Pharmaceutical Ethics,Pharmacy Ethics,Ethic, Pharmaceutic,Ethic, Pharmaceutical,Ethic, Pharmacy,Pharmaceutic Ethic,Pharmaceutical Ethic,Pharmacy Ethic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D015577 Geriatric Assessment Evaluation of the level of physical, physiological, or mental functioning in the older population group. Assessment, Geriatric,Assessments, Geriatric,Geriatric Assessments
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

S G Post, and B Beerman, and H Brodaty, and A W Gaines, and S G Gauthier, and D S Geldmacher, and S Hill, and A Homma, and M N Rossor, and P J Whitehouse, and B Winblad
Translation issues in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
S G Post, and B Beerman, and H Brodaty, and A W Gaines, and S G Gauthier, and D S Geldmacher, and S Hill, and A Homma, and M N Rossor, and P J Whitehouse, and B Winblad
Quality-of-life assessment in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
S G Post, and B Beerman, and H Brodaty, and A W Gaines, and S G Gauthier, and D S Geldmacher, and S Hill, and A Homma, and M N Rossor, and P J Whitehouse, and B Winblad
Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
S G Post, and B Beerman, and H Brodaty, and A W Gaines, and S G Gauthier, and D S Geldmacher, and S Hill, and A Homma, and M N Rossor, and P J Whitehouse, and B Winblad
Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
S G Post, and B Beerman, and H Brodaty, and A W Gaines, and S G Gauthier, and D S Geldmacher, and S Hill, and A Homma, and M N Rossor, and P J Whitehouse, and B Winblad
Cultural issues in the clinical diagnosis of Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
S G Post, and B Beerman, and H Brodaty, and A W Gaines, and S G Gauthier, and D S Geldmacher, and S Hill, and A Homma, and M N Rossor, and P J Whitehouse, and B Winblad
Diagnostic criteria for dementia in clinical trials. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
S G Post, and B Beerman, and H Brodaty, and A W Gaines, and S G Gauthier, and D S Geldmacher, and S Hill, and A Homma, and M N Rossor, and P J Whitehouse, and B Winblad
Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
S G Post, and B Beerman, and H Brodaty, and A W Gaines, and S G Gauthier, and D S Geldmacher, and S Hill, and A Homma, and M N Rossor, and P J Whitehouse, and B Winblad
length of clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
S G Post, and B Beerman, and H Brodaty, and A W Gaines, and S G Gauthier, and D S Geldmacher, and S Hill, and A Homma, and M N Rossor, and P J Whitehouse, and B Winblad
Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
S G Post, and B Beerman, and H Brodaty, and A W Gaines, and S G Gauthier, and D S Geldmacher, and S Hill, and A Homma, and M N Rossor, and P J Whitehouse, and B Winblad
Clinical trials of treatment for noncognitive symptoms of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
January 1997, Alzheimer disease and associated disorders,
Copied contents to your clipboard!